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Summary Several tumour sites have now demonstrated objective responses to alpha interferons in a diversity
of doses and schedules. Since effectiveness should be enhanced with the identification of an optimal dose
strategy, we undertook a prospectively randomized study to compare an intermittent high dose escalating
strategy (HDS) vs. a fixed low dose treatment in relation to clinical outcome and laboratory correlates of
immune function. HDS patients received interferon alpha-NI (lymphoblastoid interferon) 5 M units m-2 by
continuous i.v. infusion over 24h, escalating by 5 M units m 2day-1 as tolerated over 10 days, and repeated
every 28 days. The low dose strategy (LDS) consisted of a fixed dose of 2M units m 2 by intramuscular
injection daily for 28 days, then daily for 7 days every other week. There were 53 evaluable patients. In
keeping with earlier preliminary results there was evidence of improved immune function for HDS patients.
They demonstrated a significant increase in the number of CD2+ (sheep red blood cell binding) cells and
CD4+ (helper-inducer/suppressor-inducer) cells along with enhanced activity of natural killer cell, and mixed
leukocyte culture activity. In addition to improved immune function, HDS patients survived longer than LDS
(P=0.04). Analysis of survival in relation to response suggested that monitoring of minor responses may be
of interest for biological agents such as interferon.
Although alpha interferons have demonstrable antitumour
activity, for most neoplasms, responses have not proven
better than currently available chemotherapy (Silver, 1985).
This modest response rate could improve with the identifica-
tion of optimal doses and schedules extrapolated from
knowledge of basic cellular antitumour activity. Unfortun-
ately, investigators have been unable to identify the clinically
significant mechanisms of antitumour action from among
known interferon biological effects. The latter include direct
intracellular and membrane effects, possibly related to onco-
gene expression or related growth regulators; and indirect
host mediated activity, probably related to immune function.
The problem is important, since there is evidence that a very
different dose strategy would be appropriate to take advan-
tage of direct as opposed to indirect interferon mechanisms
of action (Golub et al., 1982; Salmon et al., 1983). In the
absence of this basic information an in vitro assay of relevant
biomodulatory activity would help establish an optimal dose
schedule.
The objectives of our prospectively randomized study of a
high vs. low dose treatment strategy were: to assess toxicity,
compare clinical effectiveness, and evaluate in vitro immune
function studies as biomodulatory correlates of clinical
activity. An evaluation of toxicity and an analysis of lym-
phocyte subsets has been reported on earlier groups of
patients (Silver et al., 1983,1985).
Materials and methods
Patient selection
To be considered for treatment histopathologic confirmation
of diagnosis was required with a measurable component of
disease, and no history of a second malignancy. Interferon
was offered only following a trial of known effective first-
line hormonal or chemotherapy and after at least two weeks
had elapsed since discontinuance of previous treatment. The
minimum age was 21. Although there was no upper age
limit, patients were required to have an ECOG (Eastern
Cooperative Oncology Group) performance status of 2 or
better and an expected survival of greater than three months.
Acceptable haematologic reserve required a total granulocyte
count of > 1,500mm 3, haemoglobin >lOgdl-1, and pla-
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telets > 125,000mm-. Patients were excluded if there was
evidence of significant sustained hypertension (blood pres-
sure > 150/100mmHg), myocardial damage by history or
ECG, or cerebrovascular accident. Limited hepatic impair-
ment was acceptable provided the serum bilirubin was
normal and alkaline phosphatase, glutamic oxaloacetic transa-
minase (GOT) and lactic acid dehydrogenase were not
greater than twice the upper limit of normal. This study was
available for patients entry after approval by Agency and
University Human Investigations Committees.
Treatment
After undergoing preliminary evaluation and giving written
informed consent patients were randomly assigned to either
a low dose or a high dose treatment strategy.
The low dose strategy (LDS) was devised to take advan-
tage of indirect antitumour activity through the stimulation
of host immunity as reported for such treatment (Golub et
al., 1982; Gresser et al., 1972), and provides a basis for
comparison with other alpha interferon studies (Borden et
al., 1982; Krown et al., 1984). Patients received 2M
unitsm-2 interferon alpha-Ni (Wellferon'h'; Burroughs Well-
come, Kent, UK) daily by intramuscular injection for an
induction period of 28 days. In the absence of disease
progression, treatment was then continued daily for 7 days
on alternate weeks until evidence of progression.
High dose strategy (HDS) treatment was based on labora-
tory data suggesting that relatively high doses provided the
optimal conditions for direct tumour cytotoxicity (Salmon et
al., 1983). Because of a wide discrepancy in reported toler-
ance (Priestman, 1980; Rohatiner et al., 1982) an escalating
schedule was selected to allow for possible individual varia-
tion. As previously detailed (Silver et al., 1983,1985), inter-
feron was given by continuous i.v. infusion to provide
intense sustained exposure. The 10 day induction treatment
began at 5M unitsm-2day-1, with subsequent daily escala-
tion of 5M unitsm-2day-1 to a total of 20M unitsm-2,
then further escalation every other day as tolerated. In the
absence of disease progression at 28 days, patients had
repeat maintenance infusions for the first 10 days of each 28
day cycle. On day 1 of the second and each subsequent
treatment cycle, patients received one-half of the maximal
tolerated dose of the previous treatment followed by escala-
tion to the previous maximal tolerated dose on the second
day if <20M units m-2 or on the third day if >20M
unitsm-2. Further escalation continued as described above.
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For either treatment arm, interferon was reduced by 50%
for total granulocyte values of <800mm-3 or platelet
counts of <00,000 mm-3, and treatment was interrupted
for granulocytes of <500mm- 3 or platelets of
<50,000mm - . Reduction or interruption of treatment
could also be at the discretion of the treating physician for
unexpected toxicity.
Blood collection
Haematologic and biochemical test panels were performed at
least 3 times per week. Blood collection for lymphocyte
studies was performed pretreatment, 6h after the 8th, 15th
and 22nd daily induction interferon injections for LDS
patients followed by pretreatment and 6h after the 7th
injection of each maintenance cycle. For HDS patients,
samples were obtained pretreatment, on day 8 (during
infusion) and day 15 (off infusion) for each 28 day cycle.
The procedure for preparing defibrinated blood and isolating
peripheral blood lymphocytes (PBL) has been described in
detail (Silver et al., 1983,1985). Flow cytometer analysis and
the NK assay were performed on freshly prepared lympho-
cytes because preliminary experiments demonstrated unac-
ceptable assay variation with cryopreserved cells.
Enumeration of cell subsets
Indirect fluorescent antibody assays on peripheral blood
lymphocytes were performed using both Orthoclone® (OKT
11, 4, 8, Ortho Pharmaceuticals Corp., Raritan, NJ) and
Coulterclone®' (T 11, 4, 8, Coulter Corp., Hialeah, FL)
monoclonal reagents. After incubation with the second anti-
body, fluorescein isothiocyanate-coupled goat antimouse
immunoglobulin (Coulter Corp.), cells were fixed with 2%
paraformaldehyde. Fluorescence analysis was performed with
a Coulter Epics V® flow cytometer, simultaneously analyzing
forward light scatter for gating of lymphocytes and fluores-
cence (Silver et al., 1983).
NK cytotoxicity assay
A 51Cr release assay was performed as previously described
(Silver et al., 1983). Briefly, K562 target cells were subcul-
tured 24-48h prior to study, then 1.5 x 106 viable cells were
washed and exposed to 0.1 mCi 51Cr. The reaction mixture,
prepared in triplicate, consisted of 104 target cells and
2.5 x 105 lymphocytes. After 4h incubation at 37°C and
centrifugation, the radioactivity of supernatant aliquots was
determined. Percentage cytotoxicity was calculated from:
(experimental release-spontaneous release)/(maximum
release-spontaneous release) x 100. Analysis of assay varia-
tion and possible systematic error were as previously des-
cribed (Silver et al., 1983).
Mixed lymphocyte culture
Target cells consisted of a cryopreserved pool of lympho-
cytes from 3 normal individuals of known HLA type. To
perform the mixed lymphocyte culture (MLC) assay 7.5 x 104
mitomycin C treated (50 ugml-1; 30min; Bristol-Myers
Pharmaceutical Gps., New York) pool cells were mixed with
an equal number of patient cells in a final volume of 200,l
RPMI 1640 (Gibco Laboratories, Grand Island, NY) supple-
mented with 20% heat inactivated (56°C; 45min) human
serum, then incubated for 5 days at 37°C in 5% CO2 and a
humidified atmosphere. Eighteen hours before the end of
incubation 3.75,uCi 3H-thymidine (Amersham Corporation,
Arlington Hts., IL) in 50 I was added to each well. After
cell collection with a Skatron (Skatron Inc., Sterling, VA)
cell harvester, the radioactivity of filter discs was determined
in a Beckman (Beckman Instruments, Palo Alto, CA) LS
3155T scintillation counter. Controls included: patient cells
alone to determine spontaneous thymidine incorporation, use
of both autologous and allogenic human AB serum to detect
possible serum stimulatory or suppressive factors, and stimu-
lation with 5% phytohaemagglutinin M (Difco Laboratories,
Detroit, MI) to evaluate response to mitogen alone. MLC
reactivity was expressed as thymidine incorporation with
exposure to pool cells minus spontaneous incorporation.
Intra-assay variation (3 repetitions of 2 samples) was 10%,
inter-assay variation over 10 assays was 19% (coefficient of
variation).
Analysis of data
Patients were randomly assigned by the envelope method
with separate sets of envelopes assigned to breast carcinoma,
ovarian carcinoma and other sites.
All patients were included in the assessment of toxicity.
Those in the study more than 10 days were also considered
evaluable for response. Five response categories were
defined. A complete response included the disappearance of
all clinical disease in the absence of new lesions lasting at
least 4 weeks. Partial responses consisted of a decrease by
>50% in the product of diameters of target measured
lesions lasting at least 4 weeks, and in the absence of
appearance of new lesions. A minimal response was defined
as a measurable decrease of at least 25% in the product of
diameters in target lesions, but insufficient to qualify as a
partial response. Patients rated as stabilization had no
significant change in disease status. Although the definition
allows for a possible increase of <25% in the product of
diameters, patients were only included in this category if it
was felt there had been a real abatement of growth rate. The
remaining patients were categorized as progression.
Survival was calculated from the date of first treatment to
death and plotted by the Kaplan Meier method. Statistical
analysis was by the log rank test.
Lymphocyte data were evaluated from the perspective of
two time periods: over the total time on study and during
each individual period of interferon administration. For the
latter analysis the results for the first treatment were
excluded since the timing for HDS and LDS were not
comparable in that case. When examining intergroup corre-
lations and trend over total time on study, all values for
each patient were subjected to analysis of covariance to test
for significant changes over time while controlling for indivi-
dual variation. Analysis of variance was used to test for
change during the shorter period of each interferon
administration.
Results
A total of 62 patients were entered on study. Of these, 9
were not evaluable for response. One patient had not met
eligibility requirements, was inappropriately randomized and
did not receive interferon. Eight (3 LDS, 5 HDS) could not
tolerate the first course (10 days) of treatment and, as
previously specified in the protocol, were evaluable for
toxicity, but not response. Intolerance was directly related to
interferon effects in 3 of the 8 patients (1 each with severe
thrombocytopenia, granulocytopenia and fatigue). Interferon
induced fatigue, immobility in bed and hypotension may
have contributed to development of multiple pulmonary
emboli in a high risk patient. All patients were closely
monitored for coagulopathy, but none was detected (Silver et
al., 1985). Complications of unanticipated extensive or
rapidly progressive disease intervened in 4 patients.
We have previously reported a detailed evaluation of dose
tolerance and toxicity in the first 37 patients entered on
study (Silver et al., 1985). For HDS patients the median
peak dose was 18M unitsm 2. There were wide interpatient
differences. While the highest dose was 56M unitsm-2, in
only 21% of the courses was the peak dose greater than 20M
unitsm 2. Both treatment arms were relatively well toler-
ated. Fever, fatigue, and malaise were predominant symp-
toms, in keeping with the experience of other investigators.
Perhaps because of very close monitoring during the first
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frequent event than generally recognized. Decreases in systo-
lic or diastolic pressures of greater than 30% were seen in
33% of LDS patients and 56% of HDS patients. Systolic or
diastolic pressures decreased by more than 30% at some
time during the treatment of 33% LDS patients and 56%
HDS patients. Blood pressures of less than 70/40mmHg
were recorded in 2 patients, both on HDS treatment.
Although blood pressure returned towards normal within
hours of discontinuing interferon, and there were no unto-
ward effects, our experience supports the need for close
monitoring of blood pressure, especially for patients receiv-
ing relatively high doses.
Response
Of the 53 patients evaluable for response 50 were females
and 3 were males with an age range of 20-73 years (median
56). All but four patients had a histologic diagnosis of either
breast carcinoma (30 patients) or ovary carcinoma (19
patients). Only one patient had not previously received
conventional first-line therapy. She had declined such treat-
ment before having heard of the interferon program. The
remaining patients had previously received either chemother-
apy (51 patients), hormone therapy alone (1 patient), both
(22 patients), or additional radiation therapy (38 patients).
Patient characteristics are detailed in Table I.
The median survival for all patients was 172 days. For
HDS patients median survival was 214 days compared with
130 days for LDS. As illustrated in Figure 1, overall survival
was significantly better for HDS patients (P=0.04 log rank
test).
The significant overall survival advantage for HDS
patients was associated with limited numbers of objective
responses (Table II). There were only 2 partial responses
lasting 18 and 44 weeks. Improvement in survival for HDS
patients could clearly not be related to partial or complete
responses. To evaluate a possible contribution of lesser
responses, we grouped minimal measurable with partial
responders and compared these total responders with the
remaining non-responsive patients. There was an overall
trend of improved response for HDS compared with LDS
patients, but this was not statistically significant. For the
breast carcinoma subgroup, however, there was a signifi-
cantly higher response rate for the HDS (P=0.03, chi
square).
There was evidence of a relationship between hormone
response and interferon response among breast carcinoma
patients. For the subgroup of 21 patients with assessable
response to previous hormone therapy, those that had
responded to hormonal manipulation also tended to respond
to interferon (P=0.005, chi square). This result could in part
be related to dose, since hormone responders were over-
represented in the HDS arm (P=0.03). To examine this




































Figure 1 Survival of patients receiving interferon. High dose
strategy (solid line) patients had significantly improved survival
(P=0.04, log rank test) compared with low dose strategy (inter-
rupted line).
Table II Treatment response
Minimal Partial
Site Progression Stabilization response response
BC
LDS 12 4 1 0
LDS 7 1 4 1
OC
LDS 4 4 3 0
HDS 2 4 1 1
Other
LDS 2 0 0 0
HDS 2 0 0 0
Abbreviations: BC=breast carcinoma, OC=ovarian carcin-
oma, LDS=low dose strategy, HDS=high dose strategy.
further, HDS patients alone were evaluated. Among this
subgroup there was significant relationship between inter-
feron and hormone responses (P=0.04).
Immune effects
Immune function data revealed additional relationships for
dose strategy and response. Over the short 7-8 day sampling
period during each interferon administration there were no
trends suggesting immune stimulation. There was a trend for
MLC and PHA suppression and this was significantly more
marked for HDS (MLC P=0.002; PHA P=0.05). Over the
longer term total time on study there were significant
immune effects. For HDS patients there was a significant
increase in the number of CD2+ (sheep red blood cell
binding) cells and CD4+ (helper-inducer/suppressor-inducer)
cells along with enhanced activity of NK and MLC (Table
III). A similar pattern was seen for responding patients
where there was an increase in CD2+ and CD4+ cells and
augmented PHA activity. The only significant change for
LDS and non-responding patients was a decrease in total
lymphocytes. In comparing dose strategies, HDS patients
developed significantly more MLC activity and LDS patients
showed a significantly greater reduction in total lymphocytes
(Table IV). Responders were distinguished from non-
responders by having developed significantly more MLC and
PHA activity.
Discussion
Our general experience with toxicity on completion of this
Values represent number of patients unless otherwise
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Table III Significance of change in lymphocyte values
Dose strategy Response
HDS LDS R NR
Lymphs 0.41 0.021 (4.2) 0.64 0.044 (2.3)
CD2 0.004T (6.8) 0.214 0.008T (7.4) 0.8T
CD4 0.002T (3.8) 0.64 0.006T (5) 0.6T
CD8 0.24 0.54 0.44 0.24
NK 0.02T (4) 0.6t * 0.9T
MLC 0.05T (21) 0.64 0.3T 0.4T
PHA * 0.914 0.001T (30) 0.8T
Statistical significance of change over total time on study
for dose strategy and response. Results are shown as P
values of either an increasing (T) or decreasing (4) trend.
Abbreviations: HDS=high dose strategy, LDS=low dose
strategy, R=responders (partial+minimal), NR=non-
responders (stabilization +progression), lymphs=total
lymphocyte count. *Significant intragroup differences do
not permit interpretation of overall trend. Values in paren-
theses are the absolute change (T-cell subset as percent of
total peripheral blood leucocytes, percent NK cytotoxicity,
or percent of pretreatment counts per minute for MLC and
PHA) predicted by the statistical model over 90 days.












Statistical significance (P value) of
differences between groups. Abbreviations:
HDS=high dose strategy, LDS=low dose
strategy, R=responders (partial+minimal),
NR=non-responders (stabilization +
progression), lymphs =total lymphocyte
count.
study is as described in our preliminary analysis of the first
37 patients (Silver et al., 1985). Although significant side
effects were seen for both dose strategies, these were cer-
tainly milder than routinely encountered with many combi-
nation chemotherapy programs. In addition to the reported
major toxicities of fever, fatigue, and leukopenia, we encoun-
tered hypotension more frequently than has been previously
reported, and this was clearly related to dose. We also found
wide individual variation in tolerance to the HDS, strongly
supporting the use of dose escalation if this strategy is to be
used.
Early reports of encouraging objective response rates for
alpha interferons in breast carcinoma (Borden et al., 1982;
Gutterman et al., 1980) have not been repeated in our own
experience (Table II). This discrepancy may in part reflect
the predominance in our study of late stage patients. Even
with the expectation of an improved response for more
limited disease, it appears unlikely that using alpha inter-
ferons as first-line agents will yield response rates compar-
able to current combination chemotherapy.
Few interferon studies have been supported by survival
analysis. It is interesting that we found a significant improve-
ment in survival for the HDS in the face of such modest
objective response rate. Our data suggest that improved
survival may be related to minor responses. These are
usually ignored in assessment of chemotherapy where direct
cell kill should produce a prompt major response. However,
biological agents can have quite different mechanisms of
action and restriction of analysis to complete or partial
responses, as defined for cytotoxic chemotherapeutic agents,
may not be sufficient for biological agents. There is animal
model evidence that interferon-induced cytostasis can
improve survival, perhaps by inducing a more differentiated
phenotype through interference with oncogene expression or
growth factors (Friedman, 1986). Such modulation of
growth and differentiation suggests that the antitumour
action of interferons may be more like that of hormones
than chemotherapeutic agents. In our study it is interesting
that patients whose tumours were sensitive to hormonal
manipulation also tended to respond to interferon and
experienced improved survival.
In experimental systems the antitumour effects of inter-
feron can be mediated indirectly through stimulation of host
immunity (Gresser et al., 1972). Comparable evidence in
humans has been inconsistent, perhaps partly because of an
emphasis on the more transient effects of interferons over
hours or days. This corresponds to our own experience over
the shorter term, where there was no indication of immune
stimulation. The trend of decreased PHA and MLC during
the short intermittent intervals of interferon administration
may be best explained by interferon antiproliferative effects
(Hokland et al., 1983). We were particularly interested in
longer term trends which would have a greater probability of
being clinically significant. Over the extended period of total
time on study there was evidence of immunostimulation for
HDS and responders. Significant increases of PHA for
responders and MLC for HDS patients suggests that in the
intervals between interferon courses patients were able to
overcome short term suppression. These findings do not
contradict the results of Einhorn et al. (1987) who found no
PHA or MLC effect over the long term, but used low doses
and daily treatment that would not allow recovery from
short term suppressive effects. Further evidence for immuno-
stimulation was in keeping with our preliminary report
(Silver et al., 1983), but unexpected on the basis of earlier
published results (Golub et al., 1982; Koren et al., 1983;
Maluish et al., 1983). However, our findings have more
recently gained support from others (Neefe et al., 1986;
Medenica & Slack, 1985).
Since the same intermittent high dose treatment strategy
resulted in both the immune effects and superior survival, it
is possible that the augmented immune status was respon-
sible for improved clinical outcome. If so, it is remarkable
that this might have been accomplished with relatively
modest absolute changes in lymphocyte values in patients
with advanced disease. The immediate importance of this
association of a biomodulatory effect with clinical response
may be its potential as a tool for identifying optimal dose
and schedules for treatment.
In our experience, interferon has limited activity as a
single agent in advanced breast and ovary carcinoma. Since
effective chemotherapy is already available for these con-
ditions, the clinical potential for interferon lies in combi-
nation with other agents and employment earlier in the
course of disease. There is evidence that interferon in
combination with chemotherapy agents or other biologicals
can be synergistic (Fleischmann et al., 1984; Namba et al.,
1983). Our data indicate that the usual chemotherapy res-
ponse criteria are not as relevant for biological therapy, and
that more attention needs to be directed at survival analysis.
In ongoing studies we are evaluating more practical sche-
dules of high dose intermittent therapy, and the use of
interferon in combination with chemotherapy (Connors &
Silver, 1984). We will further examine biomodulatory effects
to determine if they predict positive treatment outcome.
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